Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results